These Coronavirus Stocks are on Track for Record Highs in March; Amid Skyrocketing Expansion in Treatment R&D.

investingbulletin

March is kicking off with a surge of interest in Coronavirus stocks, with some companies legitimately helping the fight against the virus, while some simply seek to take advantage of the hysteria surround the virus. First, we have the obvious players who represent the largest market cap of stocks that analysts unilaterally agree will have an impact on the virus.  Alpha Pro Tech, Ltd. (NYSEMKT:APT), The Clorox Company (NYSE:CLX), Co-Diagnostics, Inc. (NASDAQ:CODX), Gilead Sciences (NASDAQ:GILD), Inovio Pharmaceuticals (NASDAQ:INO), Moderna, Inc. (NASDAQ:MRNA), and Novavax (NASDAQ:NVAX) are among the stocks that have shown a proven track record in previous outbreaks, and have the infrastructure to make an impact as the world searches for a variety of treatment options.

March stands to be the most volatile month thus far for the lesser known companies who attempt to make a name for themselves within the domain of the Coronavirus, and its derivatives. Small to Mid-Cap stocks are currently the most attarctive options for traders, as they provide the greatest return on risk during this volatile market. We will outline some of the top Coronavirus stocks to watch for significant increases in price per share during the month of March, 2020.

#1: iBio Inc. (IBIO)

Currently the most interest among mid-cap investors, IBIO focuses on developing plant-based biologics manufacturing with a new emphasis on high-quality monoclonal antibodies, vaccines, bioinks, and other proteins.

iBio Inc.’s (IBIO) annual meeting of stockholders is all set to be held on March 5, 2020, at 9:30 a.m. ET.

iBio’s FastPharming Technology has been used to produce antibody candidates for Ebola and Dengue fever viruses, as well as human and animal studies have been completed for vaccine candidates, including yellow fever virus, human papilloma virus, seasonal influenza and avian influenza.

We expect IBIO to release substantial news and updates due to the rapid pace the company has shown with its new offering, and expansion in Coronavirus related R&D. The initial volatility spike is over, due to its numerous halts (from abnormally high volume), and interest in the company to acquire new entities to enhance its second stage R&D expansion into Coronavirus treatments.


#2 Ritter Pharmaceuticals (RTTR)

Ritter Pharmaceuticals (RTTR) had a pre-coronavirus trading price of $0.21, eventually surging to $0.70. What stands out with this company is the two signed definitive agreements to merge Ritter with Qualigen, allowing Ritter to change its name once complete. Since Qualigen focuses much of its R&D on treating infectious diseases, it makes sense to see to see why analysts suggest this could be one of the leading small-cap coronavirus stocks. Since January, RTTR stock has climbed as high as $0.3659 on Feb. 27.

Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, announced that it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value. Potential strategic alternatives that may be explored or evaluated by the Company as part of this process include an acquisition, merger, reverse merger, other business combination, sale of assets, licensing or other strategic transactions involving the Company.


#3 Stemsation International (STSN)

For out third and final Coronavirus stock to watch in the month of March, we attempted to find a company that has yet to hit the radar of Coronavirus Investors. In a report issued after hours on Friday, there appears to be a major shift happening in the hunt for the Coronavirus vaccine by the use Stem Cell treatment. From this, there was a surge in Stem cell companies filing research grants for the use of stem cell XP1 and XP2 for the use of coronavirus treatments.

“Mesenchymal stem cells (MSCs) are one of the most studied and important adult stem cells. A large amount of evidence shows that MSCs can migrate to and return to damaged tissues, exert strong anti-inflammatory and immune regulatory functions, promote the regeneration and repair of damaged tissues, resist apoptosis and inhibit tissue fibrosis, and reduce tissue damage. Many studies have shown that the anti-inflammatory effects of MSCs can significantly reduce virus-induced lung injury and mortality in mice. Studies have shown that MSCs can significantly reduce acute lung injury in mice caused by H9N2 and H5N1 viruses by reducing the levels of proinflammatory cytokines and chemokines and reducing the recruitment of inflammatory cells into the lungs. Compared with MSCs from other sources, human umbilical cord-derived MSCs (umbilical cord MSCs, UC-MSCs) have been widely used because of their convenient collection, no ethical controversy, low immunogenicity, fast self-renewal and strong proliferation ability Research on the treatment of various diseases. Early research in this laboratory used UC-MSCs to intervene in endotoxin (LPS) -induced acute lung injury in mice, and confirmed that UC-MSCs can significantly reduce inflammatory cell infiltration in lung tissue, reduce inflammation in lung tissue, and significantly improve lung The structure and function of tissues protect mouse lung tissue from endotoxin-induced damage.”

In short, stem cell treatments have already shown to significantly reducie the severity of COVID-19, which has gone unnoticed until late Friday of last week. One of the few small to mid-cap Stem Cell companies to show correlations with the timing of coronavirus research is a new company called Stemsation International (STSN).

We believe in the first week of March, a significant amount of attention will be directed to Stem Cell companies, such as STSN, as new trials begin. We like STSN due to its significantly small float, and current low price. The company just recently appointed a new CEO, who recently took a health company to $65 million. Currently trading at $0.18, we expect a significant move once attention gets paid to its recent news, change in CEO, and relation to stem cell treatments.

Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

Aurora Cannabis (ACB) Current Price Risks Down-Listing to OTC markets as a "Penny Stock" Unless They Secure Financing Deal.

Aurora Cannabis ( TSE:ACB) has had a rough start to 2020, with analyst after analyst taking hits at the struggling stock. A variety of factors are to blame for this, both within and outside the companies control, however what is for certain is the risks now associated with the company due to […]

Subscribe US Now